The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Sun, Qian ^a   Li, Yan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DOXORUBICIN; MULTIDRUG RESISTANCE PROTEIN; PROTEIN KINASE C ALPHA; PSEUDOLARIC ACID B; ANTINEOPLASTIC ANTIBIOTIC; DITERPENE; HERBACEOUS AGENT;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; MOUSE; MOUSE MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; SGC7901 CELL LINE; STOMACH ADENOCARCINOMA; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS; TUMOR CELL LINE;

MUS MUSCULUS;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DITERPENES; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; P-GLYCOPROTEINS; PROTEIN KINASE C-ALPHA; SIGNAL TRANSDUCTION; STOMACH; STOMACH NEOPLASMS;

EID: 84907452291     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107830     Document Type: Article

References (35)

1. Parkin DM, Pisani P, Ferlay J (1999) Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80: 827-841.
2. Ajani JA (1998) Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 12: S44-47.
3. Borst P, Elferink RO (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592.
4. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) Pglycoprotein: from genomics to mechanism. Oncogene 22: 7468-7485.
5. Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, et al. (2004) Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: A molecular pathway of H pylori-related gastric carcinogenesis. J Pathol 202: 305-312.
6. Roy KR, Reddy GV, Maitreyi L, Agarwal S, Achari C, et al. (2010) Celecoxib inhibits MDR1 expression through COX-2-dependent mechanism in human hepatocellular carcinoma (HepG2) cell line. Cancer Chemother Pharmacol 65: 903-911.
7. Vivaldi A, Ciampi R, Tacito A, Molinaro E, Agate L, et al. (2012) Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. Mol Cell Endocrinol 355: 41-48.
8. Fine RL, Chambers TC, Sachs CW (1996) P-Glycoprotein, Multidrug Resistance and Protein Kinase C. Oncologist 1: 261-268.
9. O'Brian CA, Ward NE, Stewart JR, Chu F (2001) Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer-an evolving story. Cancer Metastasis Rev 20: 95-100.
10. Lee SK, Shehzad A, Jung JC, Sonn JK, Lee JT, et al. (2012) Protein Kinase Ca Protects Against Multidrug Resistance in Human Colon Cancer Cells. Mol Cells 34: 61-69.
11. Yang SP, Dong L, Wang Y, Wu Y, Yue JM (2003) Antifunal diterpenoids of Pseudolarix kaempferi, and their structure-activity relationship study. Bioorg Med Chem 11: 4577-4584.
12. Tan WF, Zhang XW, Li MH, Yue JM, Chen Y, et al. (2004) Pseudolaric acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factormediated anti-apoptotic effect. Eur J Pharmacol 499: 219-228.
13. Wong VK, Chiu P, Chung SS, Chow LM, Zhao YZ, et al. (2005) Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Clin Cancer Res 11: 6002-6011.
14. Yu JH, Cui Q, Jiang YY, Yang W, Tashiro S, et al. (2007) Pseudolaric acid B induces apoptosis, senescence, and mitotic arrest in human breast cancer MCF-7. Acta Pharmacol Sin 28: 1975-1983.
15. Li KS, Gu XF, Li P, Zhang Y, Zhao YS, et al. (2005) Effect of pseudolaric acid B on gastric cancer cells: inhibition of proliferation and induction of apoptosis. World J Gastroenterol 11: 7555-7559.
16. Xu YH, Wang XQ, Ju XH, Zhao LJ, Li Y (2008) Molecular mechanisms of pseudolaric acid B induced apoptosis in SGC7901 cells. Chinese Pharmacological Bulletin 24: 601-606.
17. Chen Y, Wei X, Yan P, Han Y, Sun S, et al. (2009) Human mitochondrial Mrs2 protein promotes multidrug resistance in gastric cancer cells by regulating p27, cyclin D1 expression and cytochrome C release. Cancer Biol Ther 8: 607-614.
18. Chen M, Huang SL, Zhang XQ, Zhang B, Zhu H, et al. (2012) Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1a/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 113: 2474-2487.
19. Kobunai T, Watanabe T, Fukusato T (2011) Antitumour activity of S-1 in combination with cetuximab on human gastric cancer cell lines in vivo. Anticancer Res 31: 3691-3696.
20. Hou L, Xu B, Guo W, Ran FX, Liu JT, et al. (2012) Pseudolaric acid B inhibits inducible cyclooxygenase-2 expression via downregulation of the NF-kB pathway in HT-29 cells. J Cancer Res Clin Oncol.
21. Ko JK, Leung WC, Ho WK, Chiu P (2007) Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene. Eur J Pharmacol 559: 1-13.
22. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett 580: 998-1009.
23. Breier A, Baranćk M, Sulová Z, Uhŕk B (2005) P-glycoprotein-implications of metabolism of neoplastic cells and cancer therapy. Curr Cancer Drug Targets 5: 457-468.
24. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205: 275-292.
25. Méric JB, Rottey S, Olaussen K, Soria JC, Khayat D, et al. (2006) Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 59: 51-64.
26. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, et al. (2001) Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible?. Anticancer Res 21: 2141-2147.
27. Sorokin A (2004) Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. Curr Pharm Des 10: 647-657.
28. Yu L, Wu WK, Li ZJ, Liu QC, Li HT, et al. (2009) Enhancement of doxorubicin cytotoxicity on human esophageal squamous cell carcinoma cells by indomethacin and 4-[5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-benzenesulfonamide (SC236) via inhibiting P-glycoprotein activity. Mol Pharmacol 75: 1364-1373.
29. Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, et al. (2007) Pglycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res 67: 4915-4923.
30. Clemens MJ, Trayner I, Menaya J (1992) The role of protein kinase C isoenzymes in the regulation of cell proliferation and differentiation. J Cell Sci 103: 881-887.
31. Han Y, Han ZY, Zhou XM, Shi R, Zheng Y, et al. (2002) Expression and function of classical proteinkinase C is oenzymes in gastric cancer cell line and its drug-resistant sublines. World J Gastroenterol 8: 441-445.
32. Ahmad S, Glazer RI (1993) Expression of the antisense cDNA for protein kinase C alpha attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43: 858-862.
33. Murakami M, Naraba H, Tanioka T, Semmyo N, Nakatani Y, et al. (2000) Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in cyclooxygenase-2. J Biol Chem 275: 32783-32792.
34. Kalle AM, Sachchidanand S, Pallu R (2010) Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs). Leuk Res 34: 1132-1138.
35. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, et al. (2005) Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic hl-60 cells. J Pharmacol Exp Ther 312: 346-354.